Brookhaven Accelerator Advances Cancer Care With First Human Trial of Actinium-225
On November 18, 2025, Brookhaven National Laboratory announced a major milestone in cancer research made possible by its accelerator infrastructure.Particle accelerators are not only tools for exploring the universe — they are also becoming powerful engines for medical innovation.
Brookhaven is one of just three U.S. national laboratories producing actinium-225, a rare and highly sought-after medical isotope that has shown exceptional promise in targeted cancer therapies. Actinium-225 emits alpha particles capable of destroying cancer cells while minimizing damage to surrounding healthy tissue.
For the first time ever, accelerator-produced actinium-225 will be administered to human patients as part of a groundbreaking clinical trial set to begin this year. The trial represents a significant step forward in translating advanced nuclear science into real-world medical treatments.
This achievement highlights how national laboratory research continues to bridge fundamental science and human health, offering new hope for patients and expanding the life-saving applications of particle accelerator technology.
No information from the author.
